Roche snaps up cancer drugmaker for $1.7 billion

22 December 2017
mergers-acquisitions-big

Shares of US oncology focussed firm Ignyta (Nasdaq: RXDX) leapt more than 70% in pre-market trading today, following news of a takeover bid from Swiss pharma giant Roche (ROG: SIX) which is looking to broaden its oncology portfolio, as three top-selling drugs are facing the loss patent protection.

The companies have agreed for Roche, already the world’s largest cancer drug company, to fully acquire Ignyta at a price of $ 27.00 per share in an all-cash transaction. This corresponds to a total transaction value of $ 1.7 billion on a fully diluted basis, according to a company announcement. This price represents a premium of 74% to Ignyta’s closing price on December 21 and a premium of 71% and 89% to Ignyta’s 30-day and 90-day volume weighted average share price on 21 December 2017, respectively. Ignyta shares were trading at $26.78 in mid-morning, up 72% on Thursday’s close.

The merger agreement has been unanimously approved by the boards of Ignyta and Roche, and closing of the transaction is expected to take place in the first half of 2018

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical